UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood, 2022-06, Vol.139 (25), p.3605-3616

2022

Volltextzugriff (PDF)

Development and dynamics of robust T-cell responses to CML under imatinib treatment

Blood, 2008-06, Vol.111 (11), p.5342-5349

2008

Volltextzugriff (PDF)

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood, 2023-10, Vol.142 (16), p.1359-1370

2023

Volltextzugriff (PDF)

Tnfα Promotes an Immunosuppressive Microenvironment in Cutaneous T Cell Lymphoma and Regulates PD-L1 Expression

Blood, 2020-11, Vol.136 (Supplement 1), p.33-34

2020

Volltextzugriff (PDF)

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Blood, 2013-11, Vol.122 (21), p.108-108

2013

Volltextzugriff (PDF)

The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study

Blood, 2011-11, Vol.118 (21), p.2715-2715

2011

Volltextzugriff (PDF)

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m2 Expansion Cohort of PX-171-007

Blood, 2011-11, Vol.118 (21), p.2930-2930

2011

Volltextzugriff (PDF)

ENGAGE- 501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

Blood, 2010-11, Vol.116 (21), p.3959-3959

2010

Volltextzugriff (PDF)

Disturbed NK Cell Compartment In Human CML and Bcr-Abl Positive Mice

Blood, 2010-11, Vol.116 (21), p.1207-1207

2010

Volltextzugriff (PDF)

Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma

Blood, 2010-11, Vol.116 (21), p.3024-3024

2010

Volltextzugriff (PDF)

Disturbed NK Cell Compartment in CML Patients with Anti-Leukemia Immune Responses Under Treatment with Imatinib Mesylate

Blood, 2008-11, Vol.112 (11), p.3202-3202

2008

Volltextzugriff (PDF)

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Blood, 2011-11, Vol.118 (21), p.813-813

2011

Volltextzugriff (PDF)

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Blood, 2011-11, Vol.118 (21), p.813-813

2011

Volltextzugriff (PDF)

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Blood, 2010-11, Vol.116 (21), p.1938-1938

2010

Volltextzugriff (PDF)

Robust Anti-Leukemia CD4+ and CD8+ T Cell Responses in CML Patients Treated with Imatinib Mesylate

Blood, 2006-11, Vol.108 (11), p.2199-2199

2006

Volltextzugriff (PDF)

The NK and NKT Cell Compartment Is Suppressed in CML Patients before and after Imatinib Treatment

Blood, 2004-11, Vol.104 (11), p.4667-4667

2004

Volltextzugriff (PDF)

Regulation of Chemerin Bioactivity by Plasma Carboxypeptidase N, Carboxypeptidase B (TAFIa) and Platelets

Blood, 2007-11, Vol.110 (11), p.408-408

2007

Volltextzugriff (PDF)

Anti-Leukemia Immune Responses in CML Patients Treated with Imatinib Mesylate

Blood, 2005-11, Vol.106 (11), p.1108-1108

2005

Volltextzugriff (PDF)

Heterogeneity within Antigen-Specific T Cell Responses Revealed by Differential Dynamics of TCR Downregulation

Blood, 2004-11, Vol.104 (11), p.3851-3851

2004

Volltextzugriff (PDF)

T helper 2-dominant antilymphoma immune response is associated with fatal outcome

Blood, 1997-08, Vol.90 (4), p.1611-1617

1997

Volltextzugriff (PDF)

T Helper 2-Dominant Antilymphoma Immune Response Is Associated With Fatal Outcome

Blood, 1997-08, Vol.90 (4), p.1611-1617

1997

Volltextzugriff (PDF)

Classification of lymphoid neoplasms: the microscope as a tool for disease discovery

Blood, 2008-12, Vol.112 (12), p.4384-4399

2008

Volltextzugriff (PDF)

Meeting the challenge of hematologic malignancies in sub-Saharan Africa

Blood, 2012-05, Vol.119 (22), p.5078-5087

2012

Volltextzugriff (PDF)

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

Blood, 2011-03, Vol.117 (11), p.3214-3219

2011

Volltextzugriff (PDF)

1 – 25 von 331

Suche als RSS-Feed

Aktive Filter

SpracheChinesisch

PublikationsformBerichte

PublikationsformReviews

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(331)
Mit Volltextzugriff
(316)

Publikationsform

Artikel
(331)

Sprache

Englisch
(331)
Japanisch
(37)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(96)
Hematology
(91)
Life Sciences & Biomedicine
(91)
Science & Technology
(91)
Biological And Medical Sciences
(74)
Medical Sciences
(71)
Female
(62)
Male
(62)
Adult
(57)
Middle Aged
(55)
Hematologic And Hematopoietic Diseases
(46)
Aged
(37)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(33)
Adolescent
(21)
Treatment Outcome
(21)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(16)
Animals
(16)
Survival Analysis
(16)
Transfusions. Complications. Transfusion Reactions. Cell And Gene Therapy
(16)
Child
(15)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Development and dynamics of robust T-cell responses to CML under imatinib treatment

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Tnfα Promotes an Immunosuppressive Microenvironment in Cutaneous T Cell Lymphoma and Regulates PD-L1 Expression

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m2 Expansion Cohort of PX-171-007

ENGAGE- 501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

Disturbed NK Cell Compartment In Human CML and Bcr-Abl Positive Mice

Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma

Disturbed NK Cell Compartment in CML Patients with Anti-Leukemia Immune Responses Under Treatment with Imatinib Mesylate

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Robust Anti-Leukemia CD4+ and CD8+ T Cell Responses in CML Patients Treated with Imatinib Mesylate

The NK and NKT Cell Compartment Is Suppressed in CML Patients before and after Imatinib Treatment

Regulation of Chemerin Bioactivity by Plasma Carboxypeptidase N, Carboxypeptidase B (TAFIa) and Platelets

Anti-Leukemia Immune Responses in CML Patients Treated with Imatinib Mesylate

Heterogeneity within Antigen-Specific T Cell Responses Revealed by Differential Dynamics of TCR Downregulation

T helper 2-dominant antilymphoma immune response is associated with fatal outcome

T Helper 2-Dominant Antilymphoma Immune Response Is Associated With Fatal Outcome

Classification of lymphoid neoplasms: the microscope as a tool for disease discovery

Meeting the challenge of hematologic malignancies in sub-Saharan Africa

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

Aktive Filter

Suchergebnisse filtern